Shares of HCW Biologics (HCWB) cratered 12.4% to $1.27 on June 9 after the company filed to register up to 5.7 million shares for resale, tied to a recent private placement. The drop extends a punishing slide — the stock has lost nearly 29% in just over a week from its $1.79 close on June 2 — raising pointed questions about whether this clinical-stage biotech can fund its pipeline without destroying shareholder value. HCW Biologics Registers 5.7 Million Shares for Resale as Stock Plunges — Is There Enough Left for Existing Shareholders?
Shares of HCW Biologics plunged 12.4% to $1.27 on June 9 after the company filed to register up to 5.7 million shares for resale by investors who participated in a recent private placement. The drop extends a brutal week-long slide — down 29% from $1.79 on June 2 — and raises existential questions about dilution in a company with only 7.2 million shares currently outstanding.
The New Shares Could Nearly Double the Stock's Trading Supply
As of June 3, HCW Biologics had 7,161,150 shares outstanding. The 5.7 million registered for resale represent roughly 80% of the existing float. The underlying May 21 private placement sold approximately 2.85 million units at $1.405 each — with each unit bundling one share (priced at $1.28) plus one warrant to buy another share at $1.28. In short, every new share sold came packaged with the right to buy a second share, which is why 2.85 million units translate into 5.7 million potential shares. At today's price of $1.27, those warrants are essentially worthless — but any rebound above $1.28 could trigger a fresh wave of selling.
A $4 Million Raise That Barely Moves the Needle
The placement raised roughly $4 million in gross proceeds, earmarked for clinical trials, early-stage drug studies, and select debt repayment. But the company ended Q1 with only about $1.2 million in cash and a negative working capital position of roughly -$18.2 million. Even with the new capital, management itself acknowledges "substantial doubt about going-concern status without additional funding." The math is stark: operating activities burned $1.6 million in Q1 alone , meaning the $4 million buys roughly two more quarters of runway.
A Licensing Windfall Masked the Underlying Fragility
Q1 2026's $6.5 million revenue spike "stemmed almost exclusively from one transaction" — a licensing fee from Beijing Trimmune Biotech.
That produced $3.47 million in net income, versus a $2.2 million loss a year earlier. Strip out that one-time deal, and the company's core operations still generate negligible revenue. Trailing twelve-month revenue stands at just $54,000 , underscoring how dependent the business remains on sporadic deal-making.
Nasdaq Compliance Adds Another Layer of Risk
HCW Biologics is currently appealing a Nasdaq delisting notice related to the $1.00 minimum bid price rule. Today's slide to $1.27 narrows that cushion uncomfortably. If shares breach $1.00 again, delisting proceedings could resume — further crushing liquidity and institutional interest.
The bottom line: Existing shareholders face a stock where potential supply could nearly double, cash is threadbare, and the only profitable quarter in recent memory was powered by a one-time deal.